Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Cernea

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Nature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Drug insight: New immunomodulatory therapies in type 1 diabetesSimona Cernea, Kevan C Herold
Clinical Immunology (Orlando, Fla.)|October 20, 2009
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodiesSimona Cernea, Kevan C Herold
Expert Opinion on Emerging Drugs|November 5, 2016
An update on DPP-4 inhibitors in the management of type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews|October 12, 2010
Prevention of type 1 diabetes: today and tomorrowSimona Cernea, Minodora Dobreanu, Itamar Raz
Diabetes Care|October 31, 2009
Beta-cell protection and therapy for latent autoimmune diabetes in adultsSimona Cernea, Raffaella Buzzetti, Paolo Pozzilli
Expert Opinion on Drug Safety|March 1, 2016
Saxagliptin for the treatment of diabetes - a focus on safetySimona Cernea, Avivit Cahn, Itamar Raz
Journal of Diabetes|November 23, 2019
SGLT2 inhibitors for primary prevention of cardiovascular eventsItamar Raz, Simona Cernea, Avivit Cahn
Annals of Translational Medicine|February 5, 2020
The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?Avivit Cahn, Simona Cernea, Itamar Raz
Expert Review of Clinical Pharmacology|March 10, 2017
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesSimona Cernea, Avivit Cahn, Itamar Raz
Reviews in Endocrine & Metabolic Disorders|April 24, 2016
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Nature Clinical Practice. Endocrinology & Metabolism|August 26, 2006
Drug insight: New immunomodulatory therapies in type 1 diabetesSimona Cernea, Kevan C Herold
Clinical Immunology (Orlando, Fla.)|October 20, 2009
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodiesSimona Cernea, Kevan C Herold
Expert Opinion on Emerging Drugs|November 5, 2016
An update on DPP-4 inhibitors in the management of type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews|October 12, 2010
Prevention of type 1 diabetes: today and tomorrowSimona Cernea, Minodora Dobreanu, Itamar Raz
Diabetes Care|October 31, 2009
Beta-cell protection and therapy for latent autoimmune diabetes in adultsSimona Cernea, Raffaella Buzzetti, Paolo Pozzilli
Expert Opinion on Drug Safety|March 1, 2016
Saxagliptin for the treatment of diabetes - a focus on safetySimona Cernea, Avivit Cahn, Itamar Raz
Journal of Diabetes|November 23, 2019
SGLT2 inhibitors for primary prevention of cardiovascular eventsItamar Raz, Simona Cernea, Avivit Cahn
Annals of Translational Medicine|February 5, 2020
The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease?Avivit Cahn, Simona Cernea, Itamar Raz
Expert Review of Clinical Pharmacology|March 10, 2017
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetesSimona Cernea, Avivit Cahn, Itamar Raz
Reviews in Endocrine & Metabolic Disorders|April 24, 2016
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetesAvivit Cahn, Simona Cernea, Itamar Raz
Pageof 5